Introgen Therapeutics Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Introgen Therapeutics

INGN 6.710

-2.6%

Nov 17 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jibacoa who wrote (712)	4/17/2007 5:13:15 PM
From: Jibacoa	Read Replies (2) of 802

INGN is trading at $5.40 AHs. It closed strong on the regular session & had some announcements at the AACR. It seems that the shorts may be in for some trouble tomorrow.Will see if Cramer & Feurstein can help them.<g> Therapy Shows Activity in Stage IV Lung Cancer Patients Tuesday April 17, 4:36 pm ET Clinical Data Selected for Late-Breaking Session at AACR Cancer Conference LOS ANGELES--(BUSINESS WIRE)--A cancer-suppressing gene has been successfully delivered into the tumors of stage IV lung cancer patients via Introgen Therapeutics, Inc.'s (NASDAQ:INGN - News) intravenously administered lipid nanoparticle product candidate INGN 401. In a phase 1 clinical trial conducted at The University of Texas M. D. Anderson Cancer Center, the gene, FUS1, was found to be active in patients' metastatic non-small cell lung cancer tumors. This is the first clinical demonstration that a gene can be injected intravenously and be taken up and expressed at high levels in cancer cells at distant sites. Lung cancer is the leading cause of cancer death in the United States, causing 160,000 deaths annually. Approximately 80 percent of lung cancer is of the non-small cell type. Thirteen patients were treated in this first-in-human study with no significant drug-related toxicity. Median survival time for all patients is 14.6 months which compares favorably to a seven-month median survival time for patients receiving second line therapy. All patients on the trial had been treated with front line cisplatin combination chemotherapy, which failed to halt their disease. The clinical trial continues and no maximum tolerated dose has been established. Blinded analysis of pretreatment and post-treatment biopsies of three patients' tumors show that expression of FUS1 was absent from pretreatment samples while a high level of FUS1 was expressed in tumors after treatment. FUS1 can induce apoptosis - programmed cell death - in cancer cells but is frequently lost when normal cells become cancerous. The study was presented today at the late-breaking abstract session of the annual meeting of the American Association for Cancer Research in Los Angeles. Snip Bernard

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next